AMGN · Amgen Inc
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-19 | MILES AMY E |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | HOLLEY CHARLES M |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 1,564 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | Drake Michael V |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 339 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | Garland Greg C. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. |
Common Stock
|
665 |
| 2026-05-19 | Kullman Ellen Jamison |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | Austin Wanda M |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. |
Common Stock
|
665 |
| 2026-05-19 | Klotman Mary E. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 18 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | Jacks Tyler |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 2,975 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | Druker Brian |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | ISHRAK OMAR |
Director, Executive Chairman |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-19 | ECKERT ROBERT |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
665 |
| 2026-05-07 | Santos Esteban |
EVP, Operations |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 327 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
522 |
| 2026-05-07 | Bradner James E. |
EVP, Research and Development |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
446 |
| 2026-05-07 | Graham Jonathan P |
EVP & Gen. Counsel & Sec. |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
499 |
| 2026-05-07 | Miller Derek |
SVP, Human Resources |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 99 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
151 |
| 2026-05-07 | Busch Matthew C. |
VP, Finance & CAO |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 39 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
41 |
| 2026-05-07 | Griffith Peter H. |
EVP & CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 359 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
556 |
| 2026-05-07 | REESE DAVID M |
EVP & Chief Technology Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
556 |
| 2026-05-07 | Gordon Murdo |
EVP, Global Commercial Ops |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
615 |
| 2026-05-07 | Grygiel Nancy A. |
SVP & CCO |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 58 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
88 |
| 2026-05-07 | Khosla Rachna |
SVP, Business Development |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 59 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
93 |
| 2026-05-07 | Bradway Robert A |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
2,079 |
| 2026-05-06 | Grygiel Nancy A. |
SVP & CCO |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
76 |
| 2026-05-06 | Santos Esteban |
EVP, Operations |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 388 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
427 |
| 2026-05-06 | Bradway Robert A |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 1,520 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
1,702 |
| 2026-05-06 | Miller Derek |
SVP, Human Resources |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 116 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
123 |
| 2026-05-06 | Bradner James E. |
EVP, Research and Development |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 1,332 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
407 |
| 2026-05-06 | Graham Jonathan P |
EVP & Gen. Counsel & Sec. |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 370 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
408 |
| 2026-05-06 | REESE DAVID M |
EVP & Chief Technology Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
454 |
| 2026-05-06 | Griffith Peter H. |
EVP & CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
502 |
| 2026-05-06 | Khosla Rachna |
SVP, Business Development |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
79 |
| 2026-05-06 | Gordon Murdo |
EVP, Global Commercial Ops |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 458 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
502 |
| 2026-05-06 | Busch Matthew C. |
VP, Finance & CAO |
Tax↓
Filing footnotes — Common Stock (Direct)
These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
50 |
| 2026-05-05 | Drake Michael V |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
These shares include 339 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
79 |
| 2026-05-05 | Santos Esteban |
EVP, Operations |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. |
Nqso (Right to Buy)
|
17,814 |
| 2026-05-05 | Miller Derek |
SVP, Human Resources |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. |
Nqso (Right to Buy)
|
5,938 |
| 2026-05-05 | Gordon Murdo |
EVP, Global Commercial Ops |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
3,640 |
| 2026-05-05 | Bradway Robert A |
Director |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. |
Nqso (Right to Buy)
|
79,176 |
| 2026-05-05 | Busch Matthew C. |
VP, Finance & CAO |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
455 |
| 2026-05-05 | REESE DAVID M |
EVP & Chief Technology Officer |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026. |
Nqso (Right to Buy)
|
19,002 |
| 2026-05-05 | REESE DAVID M |
EVP & Chief Technology Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027, subject to proration based on the number of completed months of active employment in 2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
2,912 |
| 2026-05-05 | Bradway Robert A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
12,136 |
| 2026-05-05 | Khosla Rachna |
SVP, Business Development |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
500 |
| 2026-05-05 | Gordon Murdo |
EVP, Global Commercial Ops |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. |
Nqso (Right to Buy)
|
23,752 |
| 2026-05-05 | Griffith Peter H. |
EVP & CFO |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
3,640 |
| 2026-05-05 | Grygiel Nancy A. |
SVP & CCO |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
485 |
| 2026-05-05 | Khosla Rachna |
SVP, Business Development |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. |
Nqso (Right to Buy)
|
3,266 |
| 2026-05-05 | Miller Derek |
SVP, Human Resources |
Award↑
Filing footnotes — Common Stock (Direct)
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
Common Stock
|
910 |
| 2026-05-05 | Busch Matthew C. |
VP, Finance & CAO |
Award↑
Filing footnotes — Nqso (Right to Buy) (Direct)
These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. |
Nqso (Right to Buy)
|
2,969 |
| 2026-05-05 | ISHRAK OMAR |
Director, Executive Chairman |
Award↑
Filing footnotes — Common Stock (Direct)
These shares include 418 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Common Stock
|
106 |